Lucid Diagnostics IncNASDAQ:LUCDNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.9990
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.9800/ 5
- Ask / Lots0.9951/ 2
- Open / Previous Close0.9800 / 0.9990
- Day Range
- 52 Week Range
- Volume643,638
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LUCD |
|---|---|---|
| 09:32 ET | 6163 | 0.99 |
| 09:37 ET | 103 | 1 |
| 09:39 ET | 2523 | 0.996 |
| 09:42 ET | 627 | 0.99505 |
| 09:44 ET | 8038 | 1 |
| 09:46 ET | 330 | 0.99 |
| 09:51 ET | 200 | 1 |
| 09:53 ET | 17035 | 0.99 |
| 09:55 ET | 900 | 0.9947 |
| 10:02 ET | 130 | 0.99 |
| 10:04 ET | 188 | 0.9979 |
| 10:06 ET | 354 | 0.98775 |
| 10:08 ET | 6964 | 0.9881 |
| 10:09 ET | 16674 | 0.9771 |
| 10:11 ET | 5600 | 0.985575 |
| 10:13 ET | 627 | 0.960001 |
| 10:15 ET | 250 | 0.97705 |
| 10:20 ET | 5728 | 0.987163 |
| 10:22 ET | 500 | 0.975 |
| 10:31 ET | 100 | 0.975 |
| 10:36 ET | 390 | 0.975 |
| 10:38 ET | 700 | 0.97 |
| 10:44 ET | 300 | 0.97 |
| 10:49 ET | 100 | 0.97 |
| 10:56 ET | 284 | 0.9749 |
| 11:00 ET | 1375 | 0.9718 |
| 11:02 ET | 500 | 0.972 |
| 11:03 ET | 1600 | 0.972 |
| 11:12 ET | 1300 | 0.972 |
| 11:14 ET | 200 | 0.972 |
| 11:16 ET | 600 | 0.972 |
| 11:18 ET | 1100 | 0.97 |
| 11:20 ET | 14800 | 0.96 |
| 11:21 ET | 1914 | 0.961 |
| 11:23 ET | 100 | 0.972 |
| 11:25 ET | 1000 | 0.971999 |
| 11:27 ET | 2875 | 0.972 |
| 11:30 ET | 100 | 0.972 |
| 11:32 ET | 100 | 0.972 |
| 11:36 ET | 1500 | 0.97 |
| 11:39 ET | 100 | 0.972 |
| 11:41 ET | 100 | 0.9662 |
| 11:43 ET | 100 | 0.97 |
| 11:52 ET | 155 | 0.972 |
| 11:56 ET | 100 | 0.9712 |
| 11:57 ET | 100 | 0.9691 |
| 12:01 ET | 300 | 0.972 |
| 12:03 ET | 2980 | 0.9712 |
| 12:10 ET | 100 | 0.9811 |
| 12:14 ET | 100 | 0.97365 |
| 12:15 ET | 18318 | 0.99505 |
| 12:17 ET | 377 | 0.9951 |
| 12:21 ET | 100 | 0.9951 |
| 12:24 ET | 364 | 0.9965 |
| 12:28 ET | 250 | 0.9931 |
| 12:30 ET | 100 | 0.993 |
| 12:32 ET | 1200 | 0.9932 |
| 12:35 ET | 2794 | 0.993 |
| 12:39 ET | 100 | 0.993 |
| 12:44 ET | 823 | 1 |
| 12:46 ET | 100 | 0.9965 |
| 12:50 ET | 3600 | 0.9973 |
| 12:51 ET | 13500 | 1.005 |
| 12:53 ET | 15500 | 1 |
| 12:55 ET | 27100 | 1 |
| 12:57 ET | 64516 | 1.0016 |
| 01:00 ET | 5700 | 0.9929 |
| 01:04 ET | 23800 | 0.9965 |
| 01:08 ET | 20000 | 1 |
| 01:09 ET | 30600 | 1.01 |
| 01:11 ET | 111670 | 1 |
| 01:13 ET | 12823 | 0.9721 |
| 01:15 ET | 700 | 0.9724 |
| 01:18 ET | 23800 | 1 |
| 01:20 ET | 212 | 1.0001 |
| 01:22 ET | 2233 | 1.0084 |
| 01:24 ET | 30359 | 0.9957 |
| 01:26 ET | 177 | 0.9961 |
| 01:29 ET | 577 | 0.9736 |
| 01:31 ET | 500 | 0.9959 |
| 01:33 ET | 200 | 0.9736 |
| 01:36 ET | 400 | 0.9736 |
| 01:38 ET | 100 | 0.97955 |
| 01:40 ET | 200 | 0.9798 |
| 01:44 ET | 1200 | 0.98 |
| 01:45 ET | 358 | 0.9801 |
| 01:47 ET | 2000 | 0.9854 |
| 01:49 ET | 200 | 0.9854 |
| 02:00 ET | 1208 | 1 |
| 02:14 ET | 2000 | 0.9916 |
| 02:16 ET | 100 | 1 |
| 02:23 ET | 100 | 0.9916 |
| 02:30 ET | 376 | 0.9916 |
| 02:41 ET | 100 | 0.9916 |
| 02:45 ET | 100 | 0.9916 |
| 02:54 ET | 6865 | 0.9999 |
| 02:57 ET | 30293 | 0.9916 |
| 02:59 ET | 3294 | 0.9917 |
| 03:03 ET | 2299 | 0.9917 |
| 03:06 ET | 100 | 0.99585 |
| 03:08 ET | 105 | 0.9959 |
| 03:10 ET | 144 | 0.991853 |
| 03:12 ET | 336 | 0.9959 |
| 03:14 ET | 343 | 1 |
| 03:15 ET | 716 | 0.99825 |
| 03:19 ET | 1278 | 0.9982 |
| 03:21 ET | 418 | 0.99825 |
| 03:24 ET | 3337 | 0.99825 |
| 03:26 ET | 400 | 0.9965 |
| 03:28 ET | 5396 | 1 |
| 03:30 ET | 200 | 1 |
| 03:32 ET | 300 | 1 |
| 03:33 ET | 2800 | 0.9963 |
| 03:35 ET | 400 | 0.9981 |
| 03:37 ET | 300 | 0.99875 |
| 03:39 ET | 8700 | 0.998 |
| 03:42 ET | 300 | 0.998 |
| 03:44 ET | 1152 | 0.9975 |
| 03:46 ET | 188 | 0.9971 |
| 03:48 ET | 300 | 0.99805 |
| 03:50 ET | 294 | 0.99805 |
| 03:51 ET | 1249 | 0.9998 |
| 03:53 ET | 18029 | 0.99925 |
| 03:55 ET | 1072 | 1 |
| 03:57 ET | 660 | 1 |
| 04:00 ET | 9152 | 0.999 |
Nov 20, 2024
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard(R) Esophageal DNA Test, from 7:56AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:56AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 18, 2024
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, from 8:15AM ET on Monday Nov 18, 2024 by Dow Jones
8:15AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 15, 2024
DJ Lucid Diagnostics Is Maintained at Overweight by Cantor Fitzgerald, from 10:01AM ET on Friday Nov 15, 2024 by Dow Jones
10:01AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
DJ Lucid Diagnostics Is Maintained at Buy by Canaccord Genuity, from 11:19AM ET on Thursday Nov 14, 2024 by Dow Jones
11:19AM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: PAVmed Provides Business Update and Third Quarter 2024 Financial Results, from 8:01AM ET on Thursday Nov 14, 2024 by Dow Jones
8:01AM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lucid Diagnostics Inc | 53.9M | -0.9x | --- |
Nutriband Inc | 53.4M | -5.9x | --- |
Modular Medical Inc | 58.1M | -2.6x | --- |
IR-Med Inc | 58.7M | -20.1x | --- |
Medinotec Inc | 58.7M | -2,688.2x | --- |
Baird Medical Investment Holdings Ltd | 59.2M | -3.1x | --- |
Company Information
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.
Contact Information
- Headquarters
- 360 Madison Avenue, 25Th FloorNEW YORK, NY, United States 10017
- Phone
- 212-949-4319
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Lishan Aklog
- President, Chief Operating Officer
- Shaun O'Neil
- Vice Chairman of the Board
- Stanley Lapidus
- Chief Financial Officer
- Dennis Mcgrath
- General Counsel, Secretary
- Michael Gordon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $53.9M |
|---|---|
Revenue (TTM) | $4.2M |
Shares Outstanding | 54.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.13 |
Book Value | $-0.05 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 12.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,103.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
